Rheumatology International

, Volume 26, Issue 12, pp 1132–1137 | Cite as

Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study

Original Article


The aim of our study was to evaluate the clinical efficacy, safety, and tolerability of ornidazole in patients with rheumatoid arthritis (RA). This was 3 months, randomized, double-blind,placebo-controlled study. A total of 160 patients with active RA were randomly assigned to receive 1,000 mg ornidazole (n = 53), 500 mg ornidazole (n = 55), or placebo (n = 52). A significantly greater percentage of patients treated with 1,000 mg ornidazole met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at 3 months compared with patients who received placebo (62.0 vs. 32.4%; P < 0.001). Greater percentages of patients treated with 1,000 mg ornidazole also achieved ACR50 responses (38.3 vs. 10.9%; P < 0.001) and ACR70 responses (19.6 vs. 1.2%; P < 0.001) compared with patients who received placebo. Ornidazole treatment was also associated with significant reductions in pain and duration of morning stiffness, significant improvement in the quality of life and both the physician’s and patient’s global assessments, and significant reductions in disease activity as assessed by objective laboratory measures (erythrocyte sedimentation rate and C-reactive protein level). Ornidazole was well tolerated. There were no dose-limiting toxic effects. In this 3-month-trial ornidazole was safe, well tolerated, and associated with improvement in the inflammatory symptoms of RA.


Ornidazole Rheumatoid arthritis Treatment 


  1. 1.
    Albani S, Carson DA (1997) Etiology and pathogenesis of rheumatoid arthritis. In Koopman WJ (ed) Arthritis and allied conditions. Williams and Wilkins, Baltimore, pp 979–992Google Scholar
  2. 2.
    Mercado FB, Marshall RI, Klestov AC, Bartold PM (2001) Relationship between rheumatoid arthritis and periodontitis. J Periodontol 72:779–787PubMedCrossRefGoogle Scholar
  3. 3.
    Greenwald RA, Kirkwood K (1999) Adult periodontitis as a model for rheumatoid arthritis (with emphasis on treatment strategies). J Rheumatol 26:1650–1653PubMedGoogle Scholar
  4. 4.
    Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. URL: http://www.medscape.com/viewarticle/505458. Accessed 2005 June 16
  5. 5.
    Moen K, Brun JG, Madland TM, Tynning T, Jonsson R (2003) Immunoglobulin G and A antibody responses to Bacteroides forsythus and Prevotella intermedia in sera and synovial fluids of arthritis patients. Clin Diagn Lab Immunol 10:1043–1050PubMedCrossRefGoogle Scholar
  6. 6.
    Hannonen P, Mottonen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501–1509PubMedCrossRefGoogle Scholar
  7. 7.
    Pinals RS, Kaplan SB, Lawson JG, Hepburn B (1986) Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 29:1427–1434PubMedCrossRefGoogle Scholar
  8. 8.
    O’Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ et al (2001) Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44:2235–2241PubMedCrossRefGoogle Scholar
  9. 9.
    Kanerud L, Scheynius A, Nord CE, Hafstrom I (1994) Effect of sulphasalazine on gastrointestinal microflora and on mucosal heat shock protein expression in patients with rheumatoid arthritis. Br J Rheumatol 33:1039–1048PubMedCrossRefGoogle Scholar
  10. 10.
    Bartlett JG (1982) Anti-anaerobic antibacterial agents. Lancet 2:478–481PubMedCrossRefGoogle Scholar
  11. 11.
    Jokipii AM, Jokipii L (1981) Metronidazole, tinidazole, ornidazole and anaerobic infections of the middle ear, maxillary sinus and central nervous system. Scand J Infect Dis Suppl 26:123–129PubMedGoogle Scholar
  12. 12.
    Kargul B, Kadir T (2001) The antibacterial effects of ornidazole on primary molars with infected pulps. Chemotherapy 47:203–207PubMedCrossRefGoogle Scholar
  13. 13.
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (pg75)-Fc fusion protein. N Engl J Med 337:141–147PubMedCrossRefGoogle Scholar
  14. 14.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumour necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRefGoogle Scholar
  15. 15.
    Seymour GJ, Gemmell E (2001) Cytokines in periodontal disease: where to from here? Acta Odontol Scand 59:167–173PubMedCrossRefGoogle Scholar
  16. 16.
    Yoshimura A, Hara Y, Kaneko T, Kato I (1997) Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria. J Periodontal Res 32:279–286PubMedCrossRefGoogle Scholar
  17. 17.
    Kjeldsen M, Holmstrup P, Lindemann RA, Bendzen K (1995) Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. J Periodontol 66:139–144PubMedGoogle Scholar
  18. 18.
    Rossano F, Rizzo A, Sanges MR, Cipollaro de L’Ero G, Tufano MA (1993) Human monocytes and gingival fibroblasts release tumor necrosis factor-alpha, interleukin-1 alpha and interleukin-6 in response to particulate and soluble fractions of Prevotella melaninogenica and Fusobacterium nucleatum. Int J Clin Lab Res 23:165–168PubMedCrossRefGoogle Scholar
  19. 19.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  20. 20.
    Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily using a modified Stanford health assessment questionnaire. Arthritis Rheum 26:1346–1353PubMedCrossRefGoogle Scholar
  21. 21.
    Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scale. J Rheumatol 9:789–793PubMedGoogle Scholar
  22. 22.
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 36:729–740PubMedCrossRefGoogle Scholar
  23. 23.
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American collage of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735PubMedCrossRefGoogle Scholar
  24. 24.
    Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP (1998) Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41:1564–1570PubMedGoogle Scholar
  25. 25.
    Jousimies-Somer HR, Finegold SM (1991). Anaerobic gram negative bacilli and cocci. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (eds) Manual of clinical microbiology. American Society for Microbiology, Washington DC, pp 538–553Google Scholar
  26. 26.
    Lorber B (2000) Bacteroides, Prevotella, Porphyromonas and Fusobacterium species (and other medically important anaerobic gram-negative bacilli). In Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennett’s principles and practice of infectious Diseases. Churchill Livingstone, Philadelphia, pp 2561–2570Google Scholar
  27. 27.
    Marsh P, Martin MV (eds) (2001) Oral microbiology. MPG Books, BodminGoogle Scholar
  28. 28.
    Zhou Z, Menard HA (2002) Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol 14:250–253PubMedCrossRefGoogle Scholar
  29. 29.
    Tighe H, Carson DA (2001) Rheumatoid factor. In: Ruddy S, Harris ED Jr, Sledge CB (eds) Kelley’s textbook of rheumatology. W.B Saunders, Philadelphia, pp 151–160Google Scholar
  30. 30.
    Bonagura VR, Artandi SE, Davidson A, Randen I, Agostino N, Thompson K et al (1993) Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis- derived monoclonal rheumatoid factors. J Immunol. 151:3840–3852PubMedGoogle Scholar
  31. 31.
    Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL (1994) Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol. 152:5988–5996PubMedGoogle Scholar
  32. 32.
    The J, Ebersole JL (1991). Rheumatoid factor (RF) distribution in periodontal disease. J Clin Immunol 11:132–142PubMedCrossRefGoogle Scholar
  33. 33.
    The J, Ebersole JL (1996). Rheumatoid factor from periodontitis patients cross-reacts with epitopes on oral bacteria. Oral Dis 2:253–262PubMedCrossRefGoogle Scholar
  34. 34.
    Yoshida A, Nakano Y, Yamashita Y, Oho T, Ito H, Kondo M et al (2001) Immunodominant region of Actinobacillus actinomycetemcomitans 40-kilodalton heat shock protein in patients with rheumatoid arthritis. J Dent Res 80:346–350PubMedCrossRefGoogle Scholar
  35. 35.
    Maeda H, Miyamoto M, Kokeguchi S, Kono T, Nishimura F, Takashiba S et al (2000) Epitope mapping of heat shock protein 60 (GroEL) from Porphyromonas gingivalis. FEMS Immunol Med Microbiol 28:219–224PubMedCrossRefGoogle Scholar
  36. 36.
    Ando T, Kato T, Ishihara K, Ogiuchi H, Okuda K (1995) Heat shock proteins in the human periodontal disease process. Microbiol Immunol. 39:321–327PubMedGoogle Scholar
  37. 37.
    Ueki K, Tabeta K, Yoshie H, Yamazaki K (2002) Self-heat shock protein 60 induces tumour necrosis factor-alpha in monocyte-derived macrophage: possible role in chronic inflammatory periodontal disease. Clin Exp Immunol 127:72–77PubMedCrossRefGoogle Scholar
  38. 38.
    Schett G, Redlich K, Xu Q, Bizan P, Groger M, Tohidast-Akrad M et al (1998) Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J Clin Invest 102:302–311PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Physical Medicine and RehabilitationNazilli State HospitalNazilliTurkey
  2. 2.NazilliTurkey

Personalised recommendations